Cytokinetics, Incorporated CYTK
56.18 USD +1.04 (+1.89%)
At closeNov 11, 2026, 7:42 AM EST
56.58 +0.40 +0.71%
Pre-market · Nov 11, 7:42 AM ET
54.12 Day range 57.21
53.55 52-week range 88.31
- YTD
- -11.58%
- 1 year
- -9.68%
News
benzinga.com Cytokinetics Presents New Aficamten Data From ACACIA-HCM And FOREST-HCM At HCMS Scientific Sessions 2026 New Analyses Across Obstructive and Non-obstructive HCM Expand Clinical Evidence for AficamtenSOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK)…
globenewswire.com Cytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026 New Analyses Across Obstructive and Non-obstructive HCM Expand Clinical Evidence for Aficamten
benzinga.com Citigroup Maintains Buy on Cytokinetics, Raises Price Target to $105 Citigroup analyst Eric Joseph maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $99 to $105.
benzinga.com Leerink Partners Maintains Outperform on Cytokinetics, Lowers Price Target to $100 Leerink Partners analyst Roanna Ruiz maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lowers the price target from $103 to $100.
seekingalpha.com Cytokinetics, Incorporated (CYTK) Q3 2026 Earnings Call Transcript Cytokinetics, Incorporated (CYTK) Q3 2026 Earnings Call Transcript
marketbeat.com Cytokinetics Q3 Earnings Call Highlights Cytokinetics NASDAQ: CYTK reported $44.5 million in third-quarter net revenue from heart drug MYQORZO, up 76% from the prior quarter, as the company prepares regulatory submissions that could expand…
zacks.com Cytokinetics (CYTK) Reports Q3 Loss, Beats Revenue Estimates Cytokinetics (CYTK) came out with a quarterly loss of $1.37 per share versus the Zacks Consensus Estimate of a loss of $1.5. This compares to a loss of $1.54 per share a year ago.
benzinga.com Cytokinetics Q3 2026 Earnings Call Transcript Cytokinetics (NASDAQ:CYTK) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com Cytokinetics Q3 EPS $(1.37) Beats $(1.44) Estimate, Sales $47.557M Beat $41.879M Estimate Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.37) per share which beat the analyst consensus estimate of $(1.44) by 4.86 percent. This is a 11.04 percent increase over losses of $(1.54)…
globenewswire.com Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update MYQORZO ® (aficamten) Net Product Revenue of $44.5 Million Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026 and Type II Variation in the European Union in Early 2027…
benzinga.com HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $140 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $140 price target.
benzinga.com Cytokinetics Receives Notice Of Compliance From Health Canada Authorizing Treatment Use Of MYQORZO For Symptomatic Obstructive Hypertrophic Cardiomyopathy Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Health Canada has issued a Notice of Compliance authorizing MYQORZO® (aficamten) for the treatment of symptomatic obstructive…
benzinga.com Here's How Much $1000 Invested In Cytokinetics 15 Years Ago Would Be Worth Today Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 15 years by 2.77% on an annualized basis producing an average annual return of 15.73%. Currently, Cytokinetics has a market…- benzinga.com Cytokinetics Presents Additional Data From Assessment Comparing Aficamten To Placebo On Cardiac Endpoints In Adults With Non-Obstructive HCM At HFSA Annual Scientific Meeting 2026 Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCMSOUTH SAN FRANCISCO, Calif., Oct. 12,…
benzinga.com Cytokinetics Q2 2026 Earnings Call: Complete Transcript On Thursday, Cytokinetics (NASDAQ:CYTK) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For…- benzinga.com RBC Capital Maintains Outperform on Cytokinetics, Raises Price Target to $113 RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and raises the price target from $112 to $113.
- benzinga.com Cytokinetics Begins ASPEN-HCM Study Evaluating MYQORZO In Adult Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy MYQORZO is a once-daily, oral allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and left…
benzinga.com Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.
benzinga.com Here’s How Much You Would Have Made Owning Cytokinetics Stock In The Last 15 Years Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 15 years by 2.64% on an annualized basis producing an average annual return of 15.99%. Currently, Cytokinetics has a market…
benzinga.com If You Invested $1000 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 10.3% on an annualized basis producing an average annual return of 23.89%. Currently, Cytokinetics has a market…
benzinga.com Cytokinetics Investors Weigh Safety Data From Pivotal Trial Cytokinetics reports Phase 3 results for aficamten in treating hypertrophic cardiomyopathy, targeting a Q4 FDA submission.
benzinga.com HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $140 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $140 price target.
benzinga.com Reported Earlier, Cytokinetics Says New Trial Data Strengthens Case For Aficamten Across Heart Condition Types Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that additional results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM)…- benzinga.com If You Invested $100 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 7.78% on an annualized basis producing an average annual return of 21.28%. Currently, Cytokinetics has a market…
- benzinga.com Barclays Maintains Overweight on Cytokinetics, Raises Price Target to $110 Barclays analyst Emily Field maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $95 to $110.
- benzinga.com JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $103 JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $97 to $103.
- benzinga.com Cytokinetics Files Delaware U.S. District Court Claim Against Bristol-Myers Squibb And MyoKardia Seeking Judgment That CYTK Isn't Infringing U.S. Patent No. 12,616,697 And That The ’697 Patent Claims Are Invalid In the complaint, the Company requests, among other things: a judgment declaring that the Company does not infringe and has not infringed any valid claim of the ’697 patent; a judgment declaring that…
- benzinga.com Truist Securities Maintains Buy on Cytokinetics, Raises Price Target to $112 Truist Securities analyst Srikripa Devarakonda maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $106 to $112.
- benzinga.com RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $112 RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lowers the price target from $117 to $112.
- benzinga.com Citizens Maintains Market Outperform on Cytokinetics, Raises Price Target to $110 Citizens analyst Jason N. Butler maintains Cytokinetics (NASDAQ:CYTK) with a Market Outperform and raises the price target from $105 to $110.
benzinga.com Needham Maintains Buy on Cytokinetics, Raises Price Target to $112 Needham analyst Serge Belanger maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $102 to $112.
benzinga.com Cytokinetics Q2 EPS $(1.50) Beats $(1.63) Estimate, Sales $28.624M Beat $17.382M Estimate Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.50) per share which beat the analyst consensus estimate of $(1.63) by 7.98 percent. This is a 33.93 percent decrease over losses of $(1.12)…- benzinga.com Here's How Much $100 Invested In Cytokinetics 10 Years Ago Would Be Worth Today Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 7.02% on an annualized basis producing an average annual return of 20.46%. Currently, Cytokinetics has a market…
- benzinga.com Cytokinetics Receives UK Marketing Authorization For MYQORZO For Treatment Of Symptomatic Obstructive Hypertrophic Cardiomyopathy In Adult Patients At the same time the National Institute for Health and Care Excellence (NICE) has issued guidance recommending aficamten for use in eligible adult patients in England and Wales.The guidance from NICE…
benzinga.com New AI ETF Bets on Healthcare's $9 Trillion Opportunity Tema's new Healthcare AI ETF (HLTH), targets AI-powered drug discovery, diagnostics, robotics and patient care.- benzinga.com RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $117 RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lowers the price target from $119 to $117.
- benzinga.com Cytokinetics To Present Late Breaking Science At ESC Congress, Including Phase 3 ACACIA‑HCM Results Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic CardiomyopathyCompany to Host In-Person and Virtual…
benzinga.com 8 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com UBS Upgrades Cytokinetics to Buy, Raises Price Target to $115 UBS analyst Ashwani Verma upgrades Cytokinetics (NASDAQ:CYTK) from Neutral to Buy and raises the price target from $69 to $115.
- benzinga.com Mizuho Maintains Outperform on Cytokinetics, Raises Price Target to $118 Mizuho analyst Salim Syed maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and raises the price target from $100 to $118.
- benzinga.com Cytokinetics Opens Applications for Corporate Giving Program, to Fund Health, Science Education and Community Nonprofits Cytokinetics, Incorporated (NASDAQ:CYTK) today announced a call for proposals for its annual Cytokinetics Corporate Giving Program. The program provides charitable donations to eligible non-profit…
- benzinga.com Cytokinetics Announces First Commercial European Launch Of MYQORZO In Germany For Treatment Of Symptomatic Obstructive Hypertrophic Cardiomyopathy In Adult Patients European Launch Follows Strong U.S. StartSOUTH SAN FRANCISCO, Calif., and ZUG, Switzerland, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the first…
- benzinga.com Citigroup Initiates Coverage On Cytokinetics with Buy Rating, Announces Price Target of $99 Citigroup analyst Eric Joseph initiates coverage on Cytokinetics (NASDAQ:CYTK) with a Buy rating and announces Price Target of $99.
- benzinga.com JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $97 JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $92 to $97.
- benzinga.com Cytokinetics Presents New Data From Its SEQUOIA-HCM Pivotal Phase 3 Clinical Study Of Aficamten In Participants With oHCM; MAPLE-HCM At European Society Of Cardiology Heart Failure 2026 Congress Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the presentation of new data reinforcing the clinical profile of MYQORZO® (aficamten) at the European Society of Cardiology (ESC) Heart…
- benzinga.com HC Wainwright & Co. Maintains Buy on Cytokinetics, Raises Price Target to $140 HC Wainwright & Co. analyst Joseph Pantginis maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $136 to $140.
- benzinga.com Wells Fargo Maintains Overweight on Cytokinetics, Raises Price Target to $105 Wells Fargo analyst Yanan Zhu maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $95 to $105.
- benzinga.com Morgan Stanley Maintains Overweight on Cytokinetics, Raises Price Target to $103 Morgan Stanley analyst Jeffrey Hung maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $90 to $103.
- benzinga.com RBC Capital Maintains Outperform on Cytokinetics, Raises Price Target to $119 RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and raises the price target from $101 to $119.
- benzinga.com Cytokinetics Q1 EPS $(1.67) Misses $(1.64) Estimate, Sales $19.355M Beat $8.518M Estimate. Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.67) per share which missed the analyst consensus estimate of $(1.64) by 1.83 percent. This is a 22.79 percent decrease over losses of…